Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning Bausch + Lomb’s disclosures often means sorting through pages of ophthalmic product data, FDA commentary and intangible-asset valuations. If you’re trying to discover how a new contact-lens material shapes margins or when a recall dents revenue, the details sit deep inside the 10-K and rolling 8-K updates. That complexity fuels searches like “Where can I find Bausch + Lomb’s quarterly earnings reports?” and “What do Bausch + Lomb executives disclose in Form 4?”. Stock Titan’s AI reads every footnote and delivers Bausch + Lomb SEC filings explained simply.
Our platform streams each filing the moment it hits EDGAR—10-Q, 10-K, 8-K, Section 16, S-1 and more—and converts them into plain-language insights. Want the highlights from a “Bausch + Lomb quarterly earnings report 10-Q filing”? We tag segment revenue and inventory shifts instantly. Need “Bausch + Lomb insider trading Form 4 transactions” or real-time alerts for “Bausch + Lomb executive stock transactions Form 4”? They arrive with context. Even dense proxies become digestible: “Bausch + Lomb proxy statement executive compensation” is broken into clear pay tables by our AI.
- AI-powered summaries translate complex notes into plain language
- Real-time alerts for every Form 4 and 8-K
- Comprehensive access to all Bausch + Lomb filings
Here, “understanding Bausch + Lomb SEC documents with AI” is routine. Jump to “Bausch + Lomb 8-K material events explained,” review a “Bausch + Lomb annual report 10-K simplified” snapshot, or export numbers for your “Bausch + Lomb earnings report filing analysis.” Investors track product-line growth, surgeons follow new device approvals, and analysts watch “Bausch + Lomb Form 4 insider transactions real-time” for sentiment shifts—all without decoding legal jargon.
Bausch + Lomb (NYSE:BLCO) filed an 8-K detailing completion of a €675 million senior secured floating-rate note offering due 2031 and a comprehensive debt refinancing.
The company also executed a Third Amendment to its credit agreement, adding $2.325 billion of term loans maturing 2031 and replacing its $500 million revolver with a new $800 million facility maturing 2030.
Proceeds were used to fully repay the outstanding revolver and refinance all term A and B loans due 2027, effectively pushing major maturities out by four years and increasing available liquidity by $300 million.
The notes bear 3-month EURIBOR + 3.875%; term loans carry SOFR + 4.25% (base-rate +3.25%). The amendment raises the maximum first-lien net leverage covenant to 5.75×, stepping down over time, and retains customary covenants and events of default.
Bausch + Lomb announced significant debt refinancing activities on June 18, 2025. The company has priced an offering of €675 million senior secured floating rate notes due 2031, increased from the initially announced €600 million. The notes will be sold at 99.500% of principal value.
The company is also pursuing a refinancing package including a $2.325 billion new term B loan facility (increased from $2.2 billion) with Term SOFR + 4.25% interest rate, and a $800 million new revolving credit facility. These proceeds will be used to:
- Repay outstanding borrowings under existing revolving credit facility
- Refinance term A loans due 2027
- Refinance term B loans due 2027
- Pay related fees and expenses
The notes offering is expected to close on June 26, 2025, subject to customary conditions. The notes will be offered to qualified institutional buyers in the US under Rule 144A and internationally under Regulation S, with first-priority liens on assets securing the company's credit agreement.
FAQ
What is the current stock price of Bausch + Lomb Corporation (BLCO)?
What is the market cap of Bausch + Lomb Corporation (BLCO)?
What are the primary business segments of Bausch + Lomb?
How does Bausch + Lomb differentiate its vision care products?
What type of surgical products does the company offer?
How extensive is Bausch + Lomb's pharmaceutical portfolio?
Who are the primary consumers of Bausch + Lomb's products?
What makes Bausch + Lomb competitive in the eye care industry?
How does the company address quality and safety in its products?
In what way does Bausch + Lomb engage with technological innovations in eye care?
